Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.85 – $2.08
Volume36,406
Market cap$19M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$19.26M
Price / earnings
—
Price / book
0.89×
Price / sales
—
EV / sales
—
EV / EBITDA
0.04×
Profitability
Earnings per share
-$3.47
Return on assets
-131.03%
Return on equity
-159.41%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.35×
Quick ratio
4.71×
Cash ratio
4.37×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$35.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ATOS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.52M
$3.8M
$5.09M
$5.28M
$3.88M
$3.54M
$3.26M
$3.75M
Research and development
$3.38M
$4.9M
$4.78M
$6.16M
$5.37M
$5.5M
$4.16M
$3.4M
Total operating expenses
$5.9M
$8.69M
$9.87M
$11.44M
$9.25M
$9.04M
$7.41M
$8.86M
Operating income
-$5.9M
-$8.69M
-$9.87M
-$11.44M
-$9.25M
-$9.04M
-$7.41M
-$8.86M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$5.64M
-$8.49M
-$9.59M
-$10.94M
-$8.69M
-$8.42M
-$6.72M
-$6.35M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.64M
-$8.49M
-$9.59M
-$10.94M
-$8.69M
-$8.42M
-$6.72M
-$6.35M
Net income attributable to common shareholders
-$5.64M
-$8.49M
-$9.59M
-$10.94M
-$8.69M
-$8.42M
-$6.72M
-$6.35M
EBITDA
-$5.9M
-$8.69M
-$9.87M
-$11.43M
-$9.25M
-$9.04M
-$7.41M
-$7.15M
Basic earnings per share
-$0.56
-$0.95
-$1.11
-$1.27
-$1.01
-$0.98
-$0.78
-$0.75
Diluted earnings per share
-$0.56
-$0.95
-$1.11
-$1.27
-$1.01
-$0.98
-$0.78
-$0.75
Recent news
Company coverage with links to the original publishers.
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
Atossa Therapeutics reported Q1 2026 results with total operating expenses of $9.9 million, up $2.5 million year-over-year. The company advanced its lead candidate (Z)-endoxifen across oncology and rare disease indications, securing FDA Orphan Drug Designation for DMD and Rare Pediatric Disease designations for both DMD and McCune-Albright Syndrome. The company strengthened its clinical leadership team and presented encouraging preclinical data for (Z)-endoxifen in DMD at the MDA conference.
Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.
Atossa Therapeutics' CEO Dr. Steven Quay will participate in a fireside chat at the 27th Annual H.C. Wainwright Global Investment Conference, discussing clinical progress of their lead product (Z)-endoxifen, a potential breast cancer treatment and prevention therapy.
Atossa Therapeutics, a clinical-stage biopharmaceutical company, announced that its Vice President of Investor and Public Relations will participate in a virtual fireside chat at the 2024 Maxim Healthcare Virtual Summit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.